| This article has been cited by |
| 1 | Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors | |
| Taymour Mostafa |
| Sexual Medicine Reviews.2017;5(2)170 |
| [DOI] |
|
| 2 | Intravenous sildenafil citrate and post-cardiac surgery acute kidney injury: a double-blind, randomised, placebo-controlled trial | |
| Tracy Kumar,Hardeep Aujla,Marcin Wozniak,Will Dott,Nikol Sullo,Lathishia Joel-David,Paolo Pais,Dawn Smallwood,Douglas Miller,Bryony Eagle-Hemming,Ana Suazo Di Paola,Shaun Barber,Cassandra Brookes,Nigel J. Brunskill,Gavin J. Murphy |
| British Journal of Anaesthesia.2020;124(6)693 |
| [DOI] |
|
| 3 | Effectiveness of Sildenafil in Pulmonary Hypertension Secondary to Valvular Heart Disease: A Systematic Review and Meta-Analysis | |
| Farizan Abdul Ghaffar,Adyani Md Redzuan,Mohd Makmor-Bakry |
| Archives Of Pharmacy Practice.2021;12(3)55 |
| [DOI] |
|
| 4 | Sildenafil: Time to Look Beyond Pulmonary Pressures | |
| Kelly Byrne,Kate Goldstone |
| Journal of Cardiothoracic and Vascular Anesthesia.2019;33(6)1657 |
| [DOI] |
|
| 5 | Sildenafil for Pulmonary Hypertension in the Early Postoperative Period After Mitral Valve Surgery | |
| Eilon Ram,Leonid Sternik,Robert Klempfner,Michael Eldar,Ilan Goldenberg,Yael Peled,Ehud Raanani,Alexander Kogan |
| Journal of Cardiothoracic and Vascular Anesthesia.2019;33(6)1648 |
| [DOI] |
|
| 6 | Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease | |
| Aaron Gopal,Tarun Sharma,Joe B. Calkins |
| Journal of Cardiovascular Pharmacology.2021;78(3)372 |
| [DOI] |
|
| 7 | PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy | |
| Daiana S. Escudero,María S. Brea,Claudia I. Caldiz,María E. Amarillo,Jorge O. Aranda,Enrique L. Portiansky,Néstor G. Pérez,Romina G. Díaz |
| European Journal of Pharmacology.2021;891(3)173724 |
| [DOI] |
|
| 8 | PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy | |
| Daiana S. Escudero,María S. Brea,Claudia I. Caldiz,María E. Amarillo,Jorge O. Aranda,Enrique L. Portiansky,Néstor G. Pérez,Romina G. Díaz |
| European Journal of Pharmacology.2021;891(3)513 |
| [DOI] |
|
| 9 | Safety and Efficacy of Sildenafil for Group 2 Pulmonary Hypertension in Left Heart Failure | |
| Kinjal Desai,Michael Di Lorenzo,Warren A. Zuckerman,Ezinne Emeruwa,Usha S. Krishnan |
| Children.2023;10(2)270 |
| [DOI] |
|
| 10 | Proconvulsant effects of sildenafil citrate on pilocarpine-induced seizures: Involvement of cholinergic, nitrergic and pro-oxidant mechanisms | |
| Michele Albuquerque Jales de Carvalho,Adriano Chaves-Filho,Alana Gomes de Souza,Camila Nayane de Carvalho Lima,Klistenes Alves de Lima,Emiliano Ricardo Rios Vasconcelos,Mariana Lima Feitosa,João Victor Souza Oliveira,Denia Alves Albuquerque de Souza,Danielle S. Macedo,Francisca Cléa Florenço de Souza,Marta Maria de França Fonteles |
| Brain Research Bulletin.2019;149(2)60 |
| [DOI] |
|
